NCT04879043 - Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

May 31, 2026

Conditions

Multiple MyelomaPlasma Cell Disorder

Interventions

DRUG

HDP-101

HDP-101 is available as lyophilized white powder for preparation of infusion.

Trial Locations (16)

1083

RECRUITING

Semmelweis University, Belgyogyaszati es Onkologiai Klinika, Budapest

1122

RECRUITING

National Institute of Oncology, Department of Oncological Internal Medicine, Budapest

10029

RECRUITING

Mount Sinai, The Tisch Cancer Instutute, New York

12203

NOT_YET_RECRUITING

Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie, Berlin

22763

RECRUITING

Asklepios Klinik Altona, Haematologie und internistische Onkologie, Hamburg

23538

RECRUITING

UKSH Campus Lübeck Klinik für Hämatologie und Onkologie, Lübeck

24105

RECRUITING

Universitätsklinikum Schleswig-Holstein, Kiel

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

50937

RECRUITING

Universitätsklinikum Köln, Cologne

55131

WITHDRAWN

Universitätsklinikum Mainz, Mainz

69120

RECRUITING

Universitätsklinikum Heidelberg, Heidelberg

77030

RECRUITING

MD Anderson Cancer Center, Houston

09116

RECRUITING

Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III, Chemnitz

40-519

RECRUITING

Pratia Onkologia Katowice, Katowice

93-513

NOT_YET_RECRUITING

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz

45-061

NOT_YET_RECRUITING

Szpital Wojewodzki w Opolu, Opole